HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Low NDI Notice Compliance Sets Stage For Enforcement – FDA’s Fabricant

This article was originally published in The Tan Sheet

Executive Summary

The volume of noncompliant supplement ingredients on the market likely will prompt an uptick in enforcement after FDA releases its NDI notification guidance, which will draw attention to the problem, dietary supplement program chief Daniel Fabricant says.

You may also be interested in...



NDI Guidance Protects Public Health And Allows Innovation – FDA's Fabricant

Present and former top FDA officials with oversight of dietary supplements defend the draft guidance on new dietary ingredient notifications, saying the document serves important public health priorities and will not be onerous to industry.

NDI Guidance Could Heighten Need To Protect DSHEA’s Intent – Harkin

Sen. Tom Harkin calls on dietary supplement industry firms to “be vigilant" in protecting their rights under the Dietary Supplement Health and Education Act once FDA publishes the new dietary ingredient notification guidance.

McCain-Dorgan NDI Guidance, Steroid Provisions In Senate Food Safety Bill

Requirements that benefit dietary supplement manufacturing and that gained Sen. John McCain's support after he initially proposed legislation considered a threat to the industry are part of the food safety reform bill pending in the Senate.

Related Content

Topics

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel